DMRA is trading 6.5% up at $25.79, extending a multi-day move sparked by its recent inclusion in multiple Russell indices.

  • Damora Therapeutics joined the Russell 2000 Growth and broader Russell 3000 family in late June 2026.
  • Index inclusion typically drives incremental buying from index funds and benchmark-aware institutions.
  • The move supports higher trading volumes and price appreciation as investors adjust portfolios around the reconstitution.